2024
Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study
Guillot J, Justice A, Gordon K, Skanderson M, Pariente A, Bezin J, Rentsch C. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study. Journal Of General Internal Medicine 2024, 1-10. PMID: 38831248, DOI: 10.1007/s11606-024-08817-4.Peer-Reviewed Original ResearchMiddle-aged patientsRisk of mortalityVeterans AffairsChronic medicationsVA patient populationIntegrated healthcare systemNational cohort studyAssociated with increased mortalityMiddle-aged individualsMechanism of injuryMiddle-aged peopleAssociated with mortalityInappropriate medicationsBeers criteriaHealthcare systemAttenuate riskCohort studyClinical characteristicsGeneral populationHyperpolypharmacyFollow-upPolypharmacyPatient populationBackgroundThe roleCox model
2022
Polypharmacy and medical intensive care unit (MICU) admission and 10-year all-cause mortality risk among hospitalized patients with and without HIV
Gordon KS, Crothers K, Butt AA, Edelman EJ, Gibert C, Pisani MM, Rodriguez-Barradas M, Wyatt C, Justice AC, Akgün KM. Polypharmacy and medical intensive care unit (MICU) admission and 10-year all-cause mortality risk among hospitalized patients with and without HIV. PLOS ONE 2022, 17: e0276769. PMID: 36302039, PMCID: PMC9612570, DOI: 10.1371/journal.pone.0276769.Peer-Reviewed Original ResearchConceptsMedical intensive care unit admissionIntensive care unit admissionCare unit admissionMICU admissionSeverity of illnessHazard ratioHIV statusUnit admissionCause mortalityHospitalized patientsElectronic health record cohortLevel of polypharmacyRetrospective cohort studyCause mortality riskCohort studyHIV infectionCox regressionPolypharmacyMortality riskFiscal year 2009AdmissionPatientsMortalitySubstance useStrong associationPotentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old
Guillot J, Rentsch CT, Gordon KS, Justice AC, Bezin J. Potentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old. Pharmacoepidemiology And Drug Safety 2022, 31: 1056-1074. PMID: 35780391, PMCID: PMC9464694, DOI: 10.1002/pds.5506.Peer-Reviewed Original ResearchConceptsLevel of polypharmacyRace/ethnicityPIM prevalencePrevalence of PIMsInappropriate medication useElectronic health recordsCommon PIMsPharmacy fillsPROMPT criteriaInappropriate medicationsOlder patientsMedication usePsychotropic medicationsRefill recordsPolypharmacyPatientsVeterans AffairsMedicationsPrevalenceHealth recordsFiscal year 2016AgeMeaningful differencesSexTarget age
2020
Polypharmacy and frailty among persons with HIV
Sung M, Gordon K, Edelman EJ, Akgün KM, Oursler KK, Justice AC. Polypharmacy and frailty among persons with HIV. AIDS Care 2020, 33: 1492-1499. PMID: 32880183, PMCID: PMC7925692, DOI: 10.1080/09540121.2020.1813872.Peer-Reviewed Original ResearchConceptsNon-ARV medicationsVeterans Aging Cohort StudyFrailty-related phenotypeLow physical activityAging Cohort StudyCross-sectional studyWarrants further studyUninfected participantsAntiretroviral therapyCohort studyRefill dataAdjusted analysisViral loadPolypharmacyPhysical activityGeneral populationMedicationsPLWHFrailtyStrong associationFurther studiesHIVPrimary predictorAssociationLarge proportion
2018
Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals
Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün KM, Gibert CL, Re V, Rimland D, Womack JA, Wyatt CM, Tate JP, Team V. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 2018, 32: 739-749. PMID: 29543653, PMCID: PMC5868488, DOI: 10.1097/qad.0000000000001756.Peer-Reviewed Original ResearchConceptsAdverse health outcomesHIV statusUninfected individualsVACS IndexMedication countUS Veterans Affairs Healthcare SystemHealth outcomesVeterans Affairs Healthcare SystemRisk of hospitalizationSeverity of illnessHIV-1 RNAHIV-positive individualsRisk of mortalityDose responseRace/ethnicityPolypharmacyFiscal year 2009HospitalizationMedicationsMortalityHealthcare systemAntiretroviralsOutcomesAssociationRisk
2013
The Next Therapeutic Challenge in HIV: Polypharmacy
Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The Next Therapeutic Challenge in HIV: Polypharmacy. Drugs & Aging 2013, 30: 613-628. PMID: 23740523, PMCID: PMC3715685, DOI: 10.1007/s40266-013-0093-9.BooksConceptsAntiretroviral therapyHIV infectionSerious adverse drug eventsChronic antiretroviral therapyHarms of polypharmacyLifelong antiretroviral therapyRisk of polypharmacyCombination antiretroviral therapyNumber of medicationsAdverse drug eventsOrgan system injuryDecades of lifePhysiologic frailtyHIV patientsMore medicationsComorbid diseasesGeriatric syndromesImmune dysfunctionMedication adherenceMost HIVTherapeutic challengeChronic inflammationSystem injuryDrug eventsPolypharmacy